Published research from the Parkinson’s Foundation shows genetic variants are more common in people with Parkinson’s disease than originally thought

Published Research from the Parkinson’s Foundation Shows Genetic Variants Are More Common in People with Parkinson’s Disease Than Originally Thought

The PD GENEration study, which tests for clinically relevant Parkinson’s genetic variants and offers genetic counseling, reached a milestone of 15,000 participants in spring 2024 and highlights the importance of sharing genetic data with participants

NEW YORK & MIAMI (July 30, 2024) – New research has found that genetic variants associated with Parkinson’s disease (PD) are more common than researchers previously believed. Investigators in the Parkinson’s Foundation-backed PD GENEration study – which reached its goal of 15,000 participants ahead of schedule this spring – found that 13% of participants have a genetic form of PD, which is a significant observation compared to long-standing estimates. Results from the first 3.5 years of the study, which examined a broad North American cohort, was published in the peer-reviewed scientific journal Brain.

PD GENEration, which tests for clinically relevant Parkinson’s-related genes, has been offered by the Parkinson’s Foundation since 2019 to any person with a confirmed PD diagnosis. The study is the first of its kind to return results at scale via live genetic counseling in English or Spanish. This enables participants and physicians to make more informed decisions about their care, including enrollment in gene-specific clinical trials.

Additional key findings from the PD GENEration study published in Brain include:

• 7.7% of participants carried a GBA1 genetic mutation, 2.1% of participants carried a PRKN genetic mutation, and 2.4% of participants carried a LRRK2 genetic mutation. All participants were informed about their genetic status through the genetic counseling component of the program.  
• The positivity rate for a genetic variant is significantly higher for individuals with high risk. Those with early-onset PD, high-risk ancestry (such as Ashkenazi Jewish, Spanish Basque, or North African Berber), or a first-degree relative affected with the disease had an 18% positivity rate. The positivity rate for individuals without one of those risk factors was nearly 10%.

• Many of these participants may qualify for precision medicine trials, showing the feasibility and importance of broadly offering genetic testing.

“We did not anticipate the high positivity rate for genetic mutations, specifically the nearly 10% having a positive result even without any known genetic risk factors,” said Roy Alcalay, MD, MS, Tel Aviv Medical Center, Israel, and the Department of Neurology, Columbia University Irving Medical Center, and lead principal investigator for PD GENEration. “Further, the speed at which participants enrolled in PD GENEration is a testament to the interest of people with PD to obtain data on their genetic status. Taken together, the positivity rate and the high interest in getting genotyped will hopefully translate to increased participation in observational studies and clinical trials toward therapies targeting these genes, simplifying precision medicine clinical trials in PD.”

“PD GENEration stands at the forefront of precision medicine and the potential for tailored treatments. In large part, this is because the Parkinson’s Foundation has recognized the importance of including genetic counseling in a research study that discloses genetic results,” said Lola Cook, MS, CGC, Department of Medical and Molecular Genetics at Indiana University, who is first author of the Brain article and one of six genetic counselors involved in the study to date. “As we’ve seen from the study’s enrollment numbers and survey results, there is a strong interest among people with PD to push the research effort forward. This includes understanding the disease’s genetics, generally and individually. It’s the idea that we are all doing our part to move toward improved treatments and a cure.”

PD GENEration is continuing into its next phase with support from the Global Parkinson’s Genetics Program (GP2), a program of the Aligning Science Across Parkinson’s (ASAP) initiative. ASAP’s funding allows the Parkinson’s Foundation to accelerate the study’s impact by focusing on those who have been historically underrepresented in research. Such enhanced wide-scale recruitment is reaching a larger and more diverse community in the United States, Canada and Latin America. The Parkinson’s Foundation aims to enroll an additional 8,000 participants, including 2,400 in Latin America, during the next phase of the study.

“PD GENEration is designed to be inclusive and accessible to all populations, with the goal of improving clinical outcomes for everyone. We are proud that the data we have collected through PD GENEration reflects the largest and most diverse North American cohort ever tested – and even though we reached our initial recruitment goal of 15,000 this spring, bigger things are on the horizon,” said James Beck, PhD, senior vice president and chief scientific officer of the Parkinson’s Foundation. “Our partnership with ASAP and GP2 allows us to reach significantly more people, further increasing the diversity of participants. Being able to understand the genetics that people with PD have in common across different populations could reveal biological secrets of the disease, with the potential to lead to new treatments.”

To learn more about PD GENEration, visit Parkinson.org/PDGENEration or call 1-800-4PD-INFO (473-4636). For questions about enrollment, email Genetics@Parkinson.org.

###

About the Parkinson’s Foundation
The Parkinson’s Foundation makes life better for people with Parkinson’s disease by improving care and advancing research toward a cure. In everything we do, we build on the energy, experience and passion of our global Parkinson’s community. Since 1957, the Parkinson’s Foundation has invested more than $449 million in Parkinson’s research and clinical care. Connect with us on Parkinson.org, Facebook, Twitter, Instagram or call 1-800-4PD-INFO (1-800-473-4636).

About Parkinson’s Disease
Affecting an estimated one million Americans, Parkinson’s disease is the second-most common neurodegenerative disease after Alzheimer’s and is the 14th-leading cause of death in the U.S. It is associated with a progressive loss of motor control (e.g., shaking or tremor at rest and lack of facial expression), as well as non-motor symptoms (e.g., depression and anxiety). There is no cure for Parkinson’s and nearly 90,000 new cases are diagnosed each year in the U.S.